TWI344954B - Asymmetric hydrogenation process - Google Patents

Asymmetric hydrogenation process Download PDF

Info

Publication number
TWI344954B
TWI344954B TW094109815A TW94109815A TWI344954B TW I344954 B TWI344954 B TW I344954B TW 094109815 A TW094109815 A TW 094109815A TW 94109815 A TW94109815 A TW 94109815A TW I344954 B TWI344954 B TW I344954B
Authority
TW
Taiwan
Prior art keywords
formula
phenyl
palm
compound
ligand
Prior art date
Application number
TW094109815A
Other languages
Chinese (zh)
Other versions
TW200606145A (en
Inventor
David M Tellers
Guy R Humphrey
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of TW200606145A publication Critical patent/TW200606145A/en
Application granted granted Critical
Publication of TWI344954B publication Critical patent/TWI344954B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00Asymmetric syntheses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/94[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered

Description

1344954 九、發明說明: 【先前技術】 具有DP受體拮抗劑活性之搂、ρ艘此丨Λ , HJ π !·玍之裱烷知吲哚衍生物揭示在ρ(:τ 申請案W003/062200中。 (〇)π1344954 IX. Description of the invention: [Prior Art] 具有 (ρ 申请 申请 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有 具有Medium. (〇)π

之所欲立體異構物 有需要一種製備此等含富鏡像異構性 之化合物的有效率的方法。 【發明内容】 本發明提供一種製傭對掌Dp受體枯抗劑及其中間物之The desired stereoisomers There is a need for an efficient process for the preparation of such compounds containing mirror image isomerism. SUMMARY OF THE INVENTION The present invention provides a servant to the palm Dp receptor antagonist and its intermediates

方法,其係藉“渡金屬催化之鏡像選擇性氫化反應。 【實施方式】 " 本發明提供-種製備至少5〇%鏡像異構物過量㈣之式I 化合物或其鹽之不對稱氫化方法 1The method is a "mirror-selective hydrogenation reaction of a metal-catalyzed reaction." [Embodiment] The present invention provides an asymmetric hydrogenation process for preparing a compound of the formula I or a salt thereof in an excess of at least 5% by% of the image isomer (4). 1

其中η為1或2,R丨為Η、Br或-S02CH3,且R2為Η、苄基、 4-硝基苄基、4-胺基苄基、4_三氟曱基苄基或4氯苄基. 100288.doc 1344954 該方法包括:以金屬-對掌配位體及氫予體處理式II化合物 mWherein η is 1 or 2, R丨 is Η, Br or -S02CH3, and R2 is oxime, benzyl, 4-nitrobenzyl, 4-aminobenzyl, 4-trifluorodecylbenzyl or 4-chloro Benzyl. 100288.doc 1344954 The method comprises: treating the compound of formula II with a metal-to-palm ligand and a hydrogen donor

jaiLjaiL

其中當該氫予體為H2時,該方法係於自約0至約500 psig(每平方英寸磅表壓)之壓力下進行,且其中該金屬-對 掌配位體為(1)釕轴向對掌膦配位體複合物或(2)铑對掌二 茂鐵基膦配位體複合物或(3)鍺-TMBTP複合物。 式I化合物(其中R1為-S02CH3,而R2為4-氣苄基或4-三氟 甲基苄基)及其醫藥上可接受鹽,為該DP受體之拮抗劑, 且可用以治療過敏性鼻炎、氣喘、菸鹼酸誘發之潮紅、及 其它經DP受體媒介之病症、障礙及疾病。式I化合物(其中 R1為Η、Br或R2為氫、苄基、4-硝基苄基或4-胺基苄基)為 中間物,其可接著轉化成所欲DP拮抗劑。 在本發明方法之一子集中,該金屬-對掌配位基為釕軸 向對掌膦配位體複合物。在其一具體實施例中,該軸性對 掌配位體係選自 BINAP、tol-BINAP、xyl-BINAP ' Synphos ' Solphos ' MeO-BIPHEP ' hexaPHEMP ' C(l-6)-tunaphos、P-Phos、xyl-P-Phos 及 TMBTP。在其第二具體 實施例中,該金屬-對掌配位體為(對-繳花烴)Ru(軸向對掌 配位體)-X2,其中X如下文定義;該配位體較佳選自 BINAP ' tol-BINAP ' xyl-BINAP ' Synphos ' Solphos ' MeO-BIPHEP、hexaPHEMP、C(l-6)-tunaphos、P-Phos、 100288.doc 1344954 xyl-P-Phos及ΤΜΒΤΡ,且χ為鹵根,例如,氣根。 在本發明方法之第二子集中,該金屬_對掌配位基為鍺_ 鐵基膦配位體複合物。在其一具體實施例中,該二茂鐵基Wherein when the hydrogen donor is H2, the process is carried out at a pressure of from about 0 to about 500 psig (pounds per square inch), and wherein the metal-to-palm ligand is (1) the 钌 axis To the palm phosphine ligand complex or (2) ruthenium ferrocene phosphine ligand complex or (3) 锗-TMBTP complex. a compound of formula I wherein R1 is -S02CH3 and R2 is 4-abenzyl or 4-trifluoromethylbenzyl, and a pharmaceutically acceptable salt thereof, is an antagonist of the DP receptor, and is useful for treating allergy Rhinitis, asthma, nicotinic acid-induced flushing, and other DP receptor-mediated disorders, disorders, and diseases. A compound of formula I wherein R1 is hydrazine, Br or R2 is hydrogen, benzyl, 4-nitrobenzyl or 4-aminobenzyl is an intermediate which can be subsequently converted to the desired DP antagonist. In a subset of the methods of the invention, the metal-to-palm ligand is a ruthenium phosphatidyl ligand complex. In one embodiment, the axial-to-palm coordination system is selected from the group consisting of BINAP, tol-BINAP, xyl-BINAP 'Synphos 'Solphos ' MeO-BIPHEP ' hexaPHEMP ' C(l-6)-tunaphos, P-Phos , xyl-P-Phos and TMBTP. In a second specific embodiment thereof, the metal-to-palm ligand is (p--hydrocarbon) Ru (axial to palm ligand)-X2, wherein X is as defined below; From BINAP ' tol-BINAP ' xyl-BINAP ' Synphos ' Solphos ' MeO-BIPHEP, hexaPHEMP, C(l-6)-tunaphos, P-Phos, 100288.doc 1344954 xyl-P-Phos and ΤΜΒΤΡ, and Halogen, for example, gas roots. In a second subset of the process of the invention, the metal-to-palm ligand is a ruthenium-iron phosphine ligand complex. In a specific embodiment thereof, the ferrocene group

Walphos、式(k)之 TMBTP複合物。在—具體實施例巾,該金屬對掌配位體Walphos, a TMBTP complex of formula (k). In the embodiment, the metal-to-palm ligand

膦配位體係選自f-BlNAPHANE josiphos、及式(I)之taniaph〇s。 在本發明方法之第三子集中,該 金屬-對掌配位體為铑_ 為[(C〇D)Rh(™BTP)]X,其中χ如下文佳為函 根,例如,氣根β 在本發明方法之第四子集中,兮 〇 . T ^_氫化反應係於驗 存在下’及視需要於I族或II族鹽存在下、 伯'卜進行。 二發第五子集係提供製備至少50%鏡像異構物 過里(ee)之式la化合物或其鹽之方法,The phosphine coordination system is selected from the group consisting of f-BlNAPHANE josiphos, and taniaph〇s of formula (I). In a third subset of the method of the invention, the metal-to-palm ligand is 铑_ is [(C〇D)Rh(TMBTP)]X, wherein χ is preferably a function root, for example, a gas radical β In a fourth subset of the process of the invention, the T.T^_hydrogenation reaction is carried out in the presence of a test and in the presence of a Group I or Group II salt, in the presence of a salt. The second subset of the second method provides a method for preparing at least 50% of the compound of the formula la (e) or a salt thereof,

氣予體處理式Ila化合物或 其包括:以金屬_對掌配位體及 其鹽Gas-treating the compound of formula Ila or comprising: a metal-to-palm ligand and a salt thereof

其中當該氯予體為H2時,該方法係於自約0至約· 100288.doc 1344954 psig(每平方英寸磅表壓)之壓力下進行,且其中該金屬-對 掌配位體為(1)釕轴向對掌膦配位體複合物或(2)铑對掌二 戊鐵基鱗配位體複合物或(3)錢_tmbTP複合物。Wherein when the chlorine precursor is H2, the method is carried out at a pressure of from about 0 to about 100288.doc 1344954 psig (pounds per square inch), and wherein the metal-to-palm ligand is ( 1) 钌 axial 对 phosphine ligand complex or (2) 铑 掌 二 戊 戊 基 基 配 或 或 or (3) _ tmbTP complex.

在其一具體實施例中’係使用釕轴向對掌膦配位體進行 化合物Ila形成化合物la之不對稱氫化反應,其中該配位體 係選自 BINAP、tol-BINAP、xyl-BINAP、Synphos、 Solphos、5_Cl,6-MeO-BIPHEP、MeO-BIPHEP、hexaPHEMP、 C(l-6)-tunaphos、P-Phos、xyl-P-Ph〇s及 TMBTP。該金屬-對 掌配位基為,例如,(對-繳花烴)RU(軸向對掌配位體)-X2,其中X如下文定義;該對掌配位體較佳為6以八卩、比1-BINAP、xyl-BINAP、Synphos、Solphos、MeO-BIPHEP、 hexaPHEMP、C( 1-6)-tunaphos、P-Phos、xyl-P-Phos 及 TMBTP,且X為鹵根,例如,氯根。In a specific embodiment thereof, the asymmetric hydrogenation reaction of compound Ila to compound la is carried out using a ruthenium axial phosphine ligand, wherein the coordination system is selected from the group consisting of BINAP, tol-BINAP, xyl-BINAP, Synphos, Solphos, 5_Cl, 6-MeO-BIPHEP, MeO-BIPHEP, hexaPHEMP, C(l-6)-tunaphos, P-Phos, xyl-P-Ph〇s and TMBTP. The metal-to-palm ligand is, for example, (p-halo-hydrocarbon) RU (axial to palm ligand)-X2, wherein X is as defined below; the pair of palm ligands is preferably 6 to eight卩, ratio 1-BINAP, xyl-BINAP, Synphos, Solphos, MeO-BIPHEP, hexaPHEMP, C(1-6)-tunaphos, P-Phos, xyl-P-Phos, and TMBTP, and X is a halide, for example, Chloride.

在其第二具體實施例中,該金屬-對掌配位體為(1)铑-二 茂鐵基-膦配位體,其中該配位體係選自f-BINAPHANE、 Walphos ' 式(k)之 josiphos、及式(1)之 taniaphos ;或(2)錢-TMBTP複合物。 在其第三具體實施例中,係於自〇至約500 psig(例如, 自約0至約250 psig或自0至約50 psig或自0至約20 psig或自 0至約10 psig)之壓力下,使用氫進行化合物Ila形成化合物 la之該不對稱氫化反應;該金屬-對掌配位體係選自(1)具 有 BINAP、tol-BINAP、xyl-BINAP、Synphos、Solphos、 MeO-BIPHEP ' hexaPHEMP、C( 1-6)-tunaphos ' P-Phos、 xyl-P-Phos 及 TMBTP 之釕複合物;(2)具有 f-BINAPHANE、 100288.doc 1344954 phos 式(k)之 josiphos、式(1)之 taniaphos 或 TMBTP 之 铑複合物。該不對稱氫化反應較佳於鹼存在下進行。 • 在本發明方法中,該"金屬-對掌配位體"為具光學活性之 釕或铑-膦複合物,其係自一觸媒先質及對掌配位體預先 $成或當場藉由化合該觸媒先質及對掌配位體而形成。該 金屬-對掌配位體之使用量通常為自約〇〇〇1至約1〇〇莫耳 較佳自約〇. 2至約5莫耳%,例如,約〇. $莫耳%。 • 合適之觸媒先質包括(但不限於)[Rh(L')X2]2、RUX3、In a second specific embodiment thereof, the metal-to-palm ligand is a (1) fluorene-ferrocenyl-phosphine ligand, wherein the coordination system is selected from the group consisting of f-BINAPHANE, Walphos' (k) Josiphos, and taniaphos of formula (1); or (2) money-TMBTP complex. In a third embodiment thereof, it is from about 500 psig (eg, from about 0 to about 250 psig or from 0 to about 50 psig or from 0 to about 20 psig or from 0 to about 10 psig) The asymmetric hydrogenation reaction of the compound 11a to form the compound la using hydrogen is carried out under pressure; the metal-to-palm coordination system is selected from the group consisting of (1) having BINAP, tol-BINAP, xyl-BINAP, Synphos, Solphos, MeO-BIPHEP'钌aPHEMP, C(1-6)-tunaphos 'P-Phos, xyl-P-Phos and TMBTP ruthenium complex; (2) with f-BINAPHANE, 100288.doc 1344954 phos formula (k) josiphos, formula (1) ) a tantalum complex of taniaphos or TMBTP. The asymmetric hydrogenation reaction is preferably carried out in the presence of a base. • In the method of the present invention, the "metal-to-palm ligand" is an optically active ruthenium or osmium-phosphine complex which is pre-formed from a catalyst precursor and a palm ligand. The spot is formed by combining the catalyst precursor and the palm ligand. The metal-to-palm ligand is typically used in an amount of from about 1 to about 1 mole, preferably from about 2 to about 5 mole percent, for example, about 〇. • Suitable catalyst precursors include (but are not limited to) [Rh(L')X2]2, RUX3,

Ru(l,)(烯丙基)2、Rh(c〇D)2X、Rh_外χ、 [Rh(c〇D)x]2 ' [Rh(NBD)x]2、[Rh(c〇E)2x]2、_(乙 烯)2¾及[Rh(售吩)2X]2’其中c〇D為M•環辛二烯,NBD 為原冰片二烯,而COE為環辛烯;又為^、Br、j、三氟甲 烷磺酸根、醋酸根、甲基磺酸根、苯磺酸根、I或 B(Ar)4 ’且L’為芳香烴(例如,苯、曱苯、繳花烴、二甲 苯、氯苯、二氯苯)、腈(例如,乙腈)、喊(例如,四氮咬 _ °南、甲基第三-丁基醚、乙醚)、胺(例如,三乙胺、二異丙 基乙胺)、稀類(例如,乙稀、丁烯、環辛稀、苯乙烯、原 冰片烯)或烯丙基(例如,甲基烯丙基)。合適的預形成金 屬·對掌配位體之實例包括(但不限於)(對掌配位體)RuX2、 (對掌配位體)RUX2⑺,其中Y為二甲基甲酿胺、三乙胺、 二甲基亞礙或丙酮’且X如上文定義。該等誠錄觸媒先 質在本技藝中皆已熟知,且市面上有售或可遵照已知文獻 之程序而製成。 ”軸向對掌膦配位體"意指具光學活性之二膦,其光學活 100288.doc 1344954 性係由約在單一化學鍵之限制旋 M. 產生可離析之鏡像異 構物所產生,向對掌膦配位體之實例包括(但不限於)表】 所示之配位體,其中Ar為,例如,苯基、間-或對甲苯 基、二甲苯基及甲氧基苯基;2為,例如,甲基、三說甲 基或甲氧基;Ra及Rb獨立為Η、甲基、三氟甲基或甲氧 基,且Rc為Η或苯基。一些特定實例為ΒΙΝΑρ(式(a),Ar=Ru(l,)(allyl)2, Rh(c〇D)2X, Rh_ outer χ, [Rh(c〇D)x]2 ' [Rh(NBD)x]2, [Rh(c〇 E) 2x]2, _(ethylene) 23⁄4 and [Rh(售)2X]2' where c〇D is M•cyclooctadiene, NBD is raw borneol, and COE is cyclooctene; ^, Br, j, trifluoromethanesulfonate, acetate, methanesulfonate, benzenesulfonate, I or B (Ar) 4 'and L' is an aromatic hydrocarbon (for example, benzene, toluene, hydrocarbons, Xylene, chlorobenzene, dichlorobenzene), nitrile (for example, acetonitrile), shouting (for example, tetrazole _ ° south, methyl third-butyl ether, diethyl ether), amine (for example, triethylamine, two Isopropylethylamine), a dilute (eg, ethylene, butene, cyclooctane, styrene, norbornene) or an allyl group (eg, methallyl). Examples of suitable preformed metal-to-palm ligands include, but are not limited to, (for palm ligands) RuX2, (palphali ligand) RUX2 (7), where Y is dimethylamine, triethylamine , dimethyl sulfoxide or acetone 'and X is as defined above. These on-demand precursors are well known in the art and are commercially available or can be made in accordance with procedures of known literature. "Axial-to-palm phosphine ligand" means an optically active diphosphine whose optical activity is 100288.doc 1344954 is produced by a confinement of a single chemical bond, M. Examples of the bromophosphine ligand include, but are not limited to, the ligands shown in the table, wherein Ar is, for example, phenyl, m- or p-tolyl, xylyl and methoxyphenyl; 2 is, for example, methyl, trimethyl or methoxy; Ra and Rb are independently fluorene, methyl, trifluoromethyl or methoxy, and Rc is hydrazine or phenyl. Some specific examples are ΒΙΝΑρ ( Formula (a), Ar=

苯基)、tol-BINAP(式(a),Ar=對-甲苯基)、χγ1·ΒΙΝΑΡ(式 (a),Ar=3,5-二曱苯基)、Η8-ΒΙΝΑΡ(式(b),Ar=苯基)、 SYNPHOSTM(式(c),Ar=苯基)、SEGPHOS(式(d),Ar=苯 基)、Solphos(式(e),Ar=苯基)、二曱苯基Solphos(式(e),Phenyl), tol-BINAP (formula (a), Ar=p-tolyl), χγ1·ΒΙΝΑΡ (formula (a), Ar=3,5-diphenylene), Η8-ΒΙΝΑΡ (formula (b) , Ar = phenyl), SYNPHOSTM (formula (c), Ar = phenyl), SEGPHOS (formula (d), Ar = phenyl), Solphos (formula (e), Ar = phenyl), diphenylene Solphos (formula (e),

Ar=3,5-二曱苯基)、MeO-BIPHEP(式(f),Ar=苯基,Z=甲 基,Ra=Rb=Rc=H)、hexaPHEMP(式(f),Ar=苯基、 Z=Ra=Rb=曱基,RC=H)、tunaphos(式(g),Ar=苯基,且π為 1 至 6)、ΤΜΒΤΡ(式(h),Ar=苯基)、P=phos(式⑴’ Ar=苯 基)、tol-P-Phos(式⑴,Ar=曱苯基)、xyU-Phos(式⑴’Ar=3,5-diphenylene), MeO-BIPHEP (formula (f), Ar=phenyl, Z=methyl, Ra=Rb=Rc=H), hexaPHEMP (formula (f), Ar=benzene Base, Z = Ra = Rb = sulfhydryl, RC = H), tunaphos (formula (g), Ar = phenyl, and π is 1 to 6), ΤΜΒΤΡ (formula (h), Ar = phenyl), P =phos (formula (1) 'Ar=phenyl), tol-P-Phos (formula (1), Ar=nonylphenyl), xyU-Phos (formula (1)'

Ar=3,5-二甲苯基)。 100288.doc 10 - 1344954Ar = 3,5-dimethylphenyl). 100288.doc 10 - 1344954

"二茂鐵基膦配位體"包括(但不限於)表2所示之配位體’ 亦即,Walphos(式(j),其中Rd及Re各為甲基或三氟曱基)、 式(k)之josiphos、式(1)之taniaphos、及 f-BINAPHANE(m)。 100288.doc 1344954" Ferrocenylphosphine ligand" including, but not limited to, the ligands shown in Table 2, that is, Walphos (formula (j), wherein each of Rd and Re is methyl or trifluoromethyl ), josiphos of formula (k), taniaphos of formula (1), and f-BINAPHANE (m). 100288.doc 1344954

表2Table 2

適於本發明之該等金屬-對掌 旱配位體在市面上有售或可 以藉由本技藝中皆已熟知之方 自一觸媒先質及對掌配 位體製纟,且其製法描述在下文之參考實例中。 該氫予體可以是氫氣、甲酸或其鹽(例如,甲酸納)或環 己-歸。較佳制氫氣。可藉由輕參考實例^所述之 程序製備式II化合物。 該不對稱氬化方法可視需要包括驗,其可以是無機或有 機驗。式!及式η之鹽係使用此等驗而形成。無機驗為,例 如,I族或π族氫氧化物、烧氧化物、芳氧化物、燒基陰離 子、芳基陰離子、冑、敍及銃衍生之葉立釋(帅)。有機 鹼包括,例如,113,3.四甲基胍(TMG)、2,3,4,6,7,89 Μ 八氫㈣醇[Μ·小丫呼(卿)、Μ•二氮雜雙卵’3 〇]壬 5-烯(DBN)、精胺酸、甜菜鹼、咖啡因、膽鹼' μ,—二苄 I00288.doc -12- 1344954 基乙二胺、二乙胺、2_二乙胺基乙醇、2_二T胺基乙醇、 乙醇胺、乙二胺、Ν_乙基嗎啉、Ν•乙基哌啶、還原葡糖 胺、葡萄糖胺、組織胺酸、海草胺(hydrabamine)、異丙 胺、二環己基、賴胺酸、苯乙胺、甲基還原葡糖胺、嗎 琳底井底°定、聚胺樹脂、普魯卡因(procaine)、嗓 呤、可可鹼、三乙胺、三甲胺' 三丙胺、三(羥甲基)胺基 甲烷、甲基苄基胺、1>4_二氮雜雙環[2 2.2]辛烷 φ (DABC0)、丁胺、二丁胺、二甲基苯基胺、二異丙胺、二 異丙基曱胺、貿子海棉、二甲胺基吡啶、第三_ 丁胺、三_ 正-丁fe、二乙醇胺、三甲基0比咬、咪吐、N_甲基咪唾、 四甲基°底咬。該不對稱氫化反應可額外包括鹽,該鹽可選 自I族或11族_化物、三氟甲烷磺酸鹽、磺酸鹽、醋酸鹽、 及硼酸鹽。 該不對稱氩化反應係在具或不具共溶劑之有機溶劑中進 行。合適之有機溶劑包括醇類’例如,甲醇、乙醇、正_ • 丙醇、異丙醇、第三_ 丁醇;酯類,例如,醋酸乙酯及醋 酸異丙酯;醯胺類’例如,二甲基甲醯胺及二甲基乙醯 胺;函化烴類,例如’二氯曱烷、二氯乙烷、及二氯苯; 喊類’例如’甲基第三-丁基醚及四氫呋喃;酮類,例 如,丙酮及2- 丁酮;芳香烴類,例如,苯、甲苯、二甲 苯;脂肪烴類’例如’己烷及庚烷;腈類,例如,乙腈; 及亞砜類,例如,二甲基亞砜。上述溶劑可單獨或以一或 夕/谷劑或與水組合之混合物使用。在一具體實施例中,該 不對稱氫化反應係在經基系溶劑(例如,甲醇)中進行。該 100288.doc •13- 1344954 反應溫度可以自約-20至約120t ;較佳自約環境溫度至約 7〇°C,且更佳自約4〇至約6(rc。該反應通常在㈣小時内 元成’ 5玄反應時間通常自約3小時至約2 4小時。 當使用氫進行該不對稱氫化反應時,其進行之壓力為自 ^ 〇至約500 psig ;在一具體實施例中,該壓力為自約〇至約 • 250 psig ;在第二具體實施例中,該壓力為自約〇至約15〇 - pSlg ’·在第三具體實施例中,該壓力為自約〇至約5〇 φ PSlg,在第四具體實施例中,該壓力為自約〇至約20 psig ;且在第五具體實施例中,該壓力為自約〇至約1〇 psig ^業經發現鏡像異構選擇性與私壓力成反比;因此增 加氫壓力通常會導致鏡像異構選擇性降低,且高於約5〇〇 psig之H2壓力會導致產物混合物含小於5〇% ee之所欲鏡像 異構物。不會受限於理論,本發明人假定該化合物(位 於該環外雙鍵之E-異構物)可藉由通過式皿環戊烯化合物 進行過渡金屬催化異構化作用而產生該對應内向-異構 • 物。該内向-異構物為可產生式I富鏡像異構性產物之氫化 基質。於低壓力下,該E-異構物形成該内向_異構物之異 構化作用比該環外雙鍵之氫化反應還快。因此,在本發明 方法之另一具體實施例中,該氫化反應係於自0至約20 psig之壓力下進行;較佳自〇至約1〇 psig。 本發明另—方面係提供一種製備至少50% ee之式I化合 物或其鹽之方法’其包括於鍺-對掌配位體複合物或釕-對 掌配位體複合物、及鹼存在下,於自約0至約20 psi之壓力 下’以氫處理式Π化合物或其鹽 '式ΠΙ化合物或其鹽或其 100288.doc -14· 1344954 混合物。The metal-to-palm ligands suitable for use in the present invention are commercially available or can be known from the prior art by a catalyst precursor and a palm coordination system, and the process is described in In the reference examples below. The hydrogen donor can be hydrogen, formic acid or a salt thereof (e.g., sodium formate) or cyclohexane. It is preferred to produce hydrogen. The compound of formula II can be prepared by lightly referring to the procedure described in Example 2. The asymmetric argonization process can be included as needed, and can be inorganic or machine tested. formula! The salt of the formula η is formed by using these tests. The inorganic test is, for example, a group I or π group hydroxide, a burnt oxide, an aryl oxide, a burnt anion, an aryl anion, a quinone, and a quinone derived leaf release (handsome). The organic base includes, for example, 113,3. tetramethylphosphonium (TMG), 2,3,4,6,7,89 Μ octahydrotetrazol (Μ·小丫呼(卿), Μ•diazepine Egg '3 〇]壬5-ene (DBN), arginine, betaine, caffeine, choline 'μ,-dibenzyl I00288.doc -12- 1344954 ethylenediamine, diethylamine, 2_two Ethylaminoethanol, 2_di-T-aminoethanol, ethanolamine, ethylenediamine, hydrazine-ethylmorpholine, hydrazine-ethylpiperidine, reduced glucosamine, glucosamine, histidine, hydrabamine , isopropylamine, dicyclohexyl, lysine, phenethylamine, methyl-reducing glucosamine, morphine bottom, polyamine resin, procaine, guanidine, theobromine, three Ethylamine, trimethylamine 'tripropylamine, tris(hydroxymethyl)aminomethane, methylbenzylamine, 1>4-diazabicyclo[2 2.2]octane φ (DABC0), butylamine, dibutylamine , dimethylphenylamine, diisopropylamine, diisopropyl decylamine, traded sponge, dimethylaminopyridine, third butylamine, tri-n-butylene, diethanolamine, trimethyl 0 Than bite, sputum, N_methyl sputum, tetramethyl bottom bite. The asymmetric hydrogenation reaction may additionally comprise a salt selected from the group consisting of Group I or Group 11 compounds, trifluoromethanesulfonates, sulfonates, acetates, and borates. The asymmetric argonization reaction is carried out in an organic solvent with or without a cosolvent. Suitable organic solvents include alcohols such as, for example, methanol, ethanol, n-propanol, isopropanol, third-butanol; esters, for example, ethyl acetate and isopropyl acetate; guanamines, for example, Dimethylmethaneamine and dimethylacetamide; functionalized hydrocarbons such as 'dichlorodecane, dichloroethane, and dichlorobenzene; screaming' such as 'methyl tert-butyl ether and Tetrahydrofuran; ketones, for example, acetone and 2-butanone; aromatic hydrocarbons such as benzene, toluene, xylene; aliphatic hydrocarbons such as 'hexane and heptane; nitriles such as acetonitrile; and sulfoxides For example, dimethyl sulfoxide. The above solvents may be used singly or as a mixture of one or a combination of granules or water. In a particular embodiment, the asymmetric hydrogenation reaction is carried out in a base solvent (e.g., methanol). The reaction temperature may range from about -20 to about 120 t; preferably from about ambient temperature to about 7 ° C, and more preferably from about 4 Torr to about 6 (rc. The reaction is usually in (d) The hourly reaction time is usually from about 3 hours to about 24 hours. When the asymmetric hydrogenation reaction is carried out using hydrogen, the pressure is from about to about 500 psig; in a specific embodiment The pressure is from about 250 to about 250 psig; in the second embodiment, the pressure is from about 〇 to about 15 〇 - pSlg '. In a third embodiment, the pressure is from about 〇 to About 5 〇 φ PSlg, in the fourth embodiment, the pressure is from about 〇 to about 20 psig; and in the fifth embodiment, the pressure is from about 〇 to about 1 〇 psig. The selectivity is inversely proportional to the private pressure; therefore, increasing the hydrogen pressure generally results in a decrease in the mirror image isomerism selectivity, and a H2 pressure above about 5 psig results in a product mixture containing less than 5% ee. Without being bound by theory, the inventors hypothesized that the compound (E-different to the double bond outside the ring) The corresponding inward-isomeric substance can be produced by transition metal catalytic isomerization by a dish cyclopentene compound. The intrinsic-isomer is a hydrogenation which produces a product of the image-rich isomerization of formula I. Substrate. Under low pressure, the isomerization of the E-isomer forms the inward-isomerization faster than the hydrogenation of the exocyclic double bond. Thus, in another embodiment of the method of the invention The hydrogenation reaction is carried out at a pressure of from 0 to about 20 psig; preferably from about 1 to about 1 psig. Another aspect of the invention provides a method of preparing a compound of formula I or a salt thereof of at least 50% ee. The invention comprises the treatment of a hydrazine compound or a salt thereof by hydrogen at a pressure of from about 0 to about 20 psi in the presence of a ruthenium-to-palm ligand complex or a ruthenium-to-palm ligand complex, and a base. A hydrazine compound or a salt thereof or a mixture thereof of 100288.doc -14· 1344954.

在該情況下,進行低壓力不對稱氫化反應時,該壓力較 佳為自0至約10 psi,且所有其它反應條件如前述。 參考實例1 化合物(13)之製法 (1)In this case, when a low pressure asymmetric hydrogenation reaction is carried out, the pressure is preferably from 0 to about 10 psi, and all other reaction conditions are as described above. Reference Example 1 Preparation of Compound (13) (1)

CIS03H, S02Cf2 60°C, 3 hr (4)CIS03H, S02Cf2 60°C, 3 hr (4)

NaOH F-NaOH F-

ONa Na OMe + (C〇2Et)2--e〇hp 20-25°CONa Na OMe + (C〇2Et)2--e〇hp 20-25°C

OMe/OEt HCOCOgNa 丨 H20, K2HP〇4 pH9.4-6.5OMe/OEt HCOCOgNa 丨 H20, K2HP〇4 pH9.4-6.5

S02CIS02CI

,so2ch3 BrCH2C02H H20, 90°C, 10h,so2ch3 BrCH2C02H H20, 90°C, 10h

NHNH2 ΗΟΙ,δΟΐ; .CH, S02CH3 .S02CH3 - -NH-N=a TBAl, THF, 50°C, 5h p-CI-C6H4CH2CI, NaOH(5N)NHNH2 ΗΟΙ,δΟΐ; .CH, S02CH3 .S02CH3 - -NH-N=a TBAl, THF, 50°C, 5h p-CI-C6H4CH2CI, NaOH(5N)

NaHC03 NaS03 " H20, 30°C, 2hNaHC03 NaS03 " H20, 30°C, 2h

CH3C(0)CH3 (11)CH3C(0)CH3 (11)

CH 3CH 3

MeS03H, MTBE N-NH3+ -SOaCHgso2chS^||(12) 100288.doc •15- 1344954MeS03H, MTBE N-NH3+ -SOaCHgso2chS^||(12) 100288.doc •15- 1344954

步驟1. (2E)-(2-氧基環亞戊基)醋酸(化合物3)之製法 將甲苯(每克環戊酮12.5毫升)、環戊酮(1當量)及草酸二 乙酿(1當量)裝入圓底燒瓶内。於2〇。〇在氮氣下攪拌均勻溶 液°以一小時,藉由添加漏斗添加甲氧基鈉(在甲醇中30 重量%,1當量)。使所形成漿體溫熱至451,並老化一小 時。使該漿體冷卻至15至2〇t,並老化一小時。過濾該漿 體’並以甲苯(每克環戊綱7.5毫升)洗務爐餅。以甲苯(每 克環戊酮7.5毫升)洗滌該濾餅,並在氮氣流中乾燥一小 時,然後於451下真空乾燥一夜,得到如淺黃色結晶狀固 體約2 : 1之甲基酯對乙基酯之混合物的化合物(2)。 將乙醛酸(50重量%之水溶液,丨.28當量)裝入圓底燒瓶 内。添加水(每毫升水性乙醛酸3.17毫升),並使該溶液冷 部至〇至5°C。以約一小時緩慢添加5N氫氧化鈉(128當 量)維持反應溫度於10 °c以下。於添加期間,監測該 阳。將最終pH調整至45(+/〇…使所形成乙路酸納溶液 冷—部至_2°C °於室溫下,將化合物(2)( 一當量)及去離子水 (母莫耳化合物(2)1升)裝入個別容器内。使該溶液冷卻至 1〇 C。於10 C下,添加二鹼價的磷酸鉀(1.75當量)至該溶 100288.doc -16 - 1344954 液内。使所形成混濁溶液冷卻至_3 °C,並於-3。(:下,以約 30分鐘添加乙酸酸納溶液至其中。添加後,於_3至0°C下 將該批混合物老化一小時。使該批混合物混熱至1 〇 ,並 添加甲基第三-丁基醚(MTBE,每莫耳化合物(2)526毫 升)。添加磷酸(85%,2.65當量)以調整pH至3.0(+/-0.1)。 充份混合該等相,費時30分鐘,並使其分離。以MTBE(每 莫耳化合物(2)405毫升)萃取該下水性層,並化合該等 MTBE層。以5%鹽水水溶液洗滌該MTBE層兩次,並&quot;照原 樣”使用。 步驟2·化合物(12)之製法 於氮氣下,先後將氣磺酸(3當量)及亞疏醯氯(ι·5當量) 裝入圓底燒瓶内。將該溶液加熱至至高+5 5至+60 °C,並以 2小時’一滴滴添加1,4-二氟苯(1當量)。完成添加後,於 + 6 0 C下使該反應混合物再老化一小時,並使其冷卻至室 溫。以一小時’將該批混合物加入曱基第三-丁基醚(每莫 耳二氟苯1升)及水(每莫耳二氟苯1升)之冷(+5°c )雙相溶液 内。分離各該層’並以水(每莫耳二氟苯1升,兩次)洗滌有 機層。 在個別容器中製備亞硫酸鈉(一當量)及碳酸氫鈉(2當量) 之水(每莫耳二氟苯之溶液。於約+25〇CT,以一小時 添加該含化合物(5)之MTBE層至該溶液内,同時授拌。於 至/凰下再授拌該雙相溶液’費時一小時’並分離各層。於 下一步驟照原樣使用該含化合物(6)之水溶液。 添加氫氧化鈉(50% ’ 1.2當量)、及溴醋酸(1 ·2當量)至該 100288.doc -17· 1344954 含有化合物(6)之水溶液内。將該反應混合物(pH〜8.2〇)加 熱至至尚+90 C,老化10小時,並使其冷卻至室溫以晶化 該產物,將其過濾,經水(每莫耳二氟苯〇.5升)洗滌,並於 ’ +30至40°C在真空下乾燥(熔點〜60°C)以得到化合物(7)。 ^ 將N-甲基吡咯烷酮(NMP,每莫耳化合物(7)8〇〇毫升)' . 化合物(7)(一當量)、及聯胺(35%水溶液,2.5當量)裝入圓 底鐵氟龍(Teflon)燒瓶内。將該溶液加熱至至高9〇&lt;t,並 φ 於氮氣下老化6小時。然後使該反應混合物冷卻至室溫, 並緩慢添加(〜1小時)丙酮(2當量)。添加丙酮後,該腙開始 晶化。於室溫下老化一小時後,添加〗小時)水(每莫耳化 合物(7)1.5升)。使該混合物老化一小時,過濾,並經水之 洗滌兩次,然後於+4(TC在真空下乾燥,得到化合物 (11)。 於氮氣下將THF(每莫耳化合物(11)1 25升)、化合物 (11)(备里)、四丁基碘化銨(0.03當量)、4-氣苄基氣(1.05 • 當量)、及5N NaOH(5當量)裝入反應容器内。使所形成雙 相混合物加熱至50°C,並攪拌5小時。然後使該混合物冷 卻至室溫,並分離該水性層。以15% NaC1水溶液(每莫耳 化合物(11)1升)洗滌該有機層。使該有機混合物加熱至至 尚50 C,並以0.5小時添加甲基磺酸(MSA,1丨當量)。完 成添加後,添加0.1重量鹽晶種以引發晶化反應。 於50 C下使該批混合物老化2小時,然後以一小時添加 MTBE(每莫耳化合物⑴)4升)。於⑽下再經2小時後,使 該批混合物冷卻至室溫,並老化2小時。過遽該混合物, 100288.doc -18· 1344954 並以MTBE洗滌該濾餅兩次,然後於十利它在真空下乾燥, 得到該聯胺/MSA鹽(化合物(12))。Step 1. Preparation of (2E)-(2-oxocyclopentylene)acetic acid (Compound 3) Toluene (12.5 ml per gram of cyclopentanone), cyclopentanone (1 equivalent) and diethyl oxalate (1) Equivalent) was charged into a round bottom flask. At 2〇. The hydrazine was stirred under nitrogen for a period of one hour, and sodium methoxide (30% by weight in methanol, 1 equivalent) was added by a funnel. The resulting slurry was allowed to warm to 451 and aged for an hour. The slurry was allowed to cool to 15 to 2 Torr and aged for one hour. The slurry was filtered and the cake was washed with toluene (7.5 ml per gram of cyclopentane). The filter cake was washed with toluene (7.5 ml per gram of cyclopentanone) and dried in a stream of nitrogen for one hour, then dried under vacuum at 451 overnight to give a methyl ester of br. Compound (2) of a mixture of base esters. Glyoxylic acid (50% by weight aqueous solution, 丨.28 equivalent) was placed in a round bottom flask. Water (3.17 ml of aqueous glyoxylate per ml) was added and the solution was allowed to cool to 5 °C. 5N sodium hydroxide (128 equivalents) was slowly added over about one hour to maintain the reaction temperature below 10 °C. The yang is monitored during the addition. Adjust the final pH to 45 (+ / 〇 ... so that the formed sodium thioate solution is cold - to _2 ° C ° at room temperature, compound (2) (one equivalent) and deionized water (mother Compound (2) 1 liter) was placed in an individual container. The solution was cooled to 1 ° C. At 10 C, dibasic potassium phosphate (1.75 equivalents) was added to the solution 100288.doc -16 - 1344954 The resulting turbid solution was cooled to _3 ° C, and a sodium acetate solution was added thereto at -3 (by: about 30 minutes). After the addition, the batch was aged at _3 to 0 ° C. One hour. The batch was allowed to heat to 1 Torr, and methyl third-butyl ether (MTBE, 526 ml per mole of compound (2)) was added. Phosphoric acid (85%, 2.65 eq.) was added to adjust the pH to 3.0 (+/- 0.1) The phases were thoroughly mixed and took 30 minutes and allowed to separate. The lower aqueous layer was extracted with MTBE (405 ml per mole of compound (2)), and the MTBE layers were combined. The MTBE layer was washed twice with a 5% brine solution and &quot;as it was." Step 2· Preparation of Compound (12) Under a nitrogen atmosphere, gas sulfonic acid (3 equivalents) Sub-branched chlorine (1·5 equivalent) was placed in a round bottom flask. The solution was heated to a temperature of +5 5 to +60 ° C and 1,4-difluorobenzene (1 equivalent) was added dropwise over 2 hours. After completion of the addition, the reaction mixture was further aged at +60 C for one hour and allowed to cool to room temperature. The batch was added to the decyl-tert-butyl ether (per mole) for one hour. 1 liter of difluorobenzene) and a cold (+5 °c) biphasic solution of water (1 liter per mole of difluorobenzene). Separate each layer 'with water (1 liter per mole of difluorobenzene, two (2) Washing the organic layer. Prepare sodium sulfite (one equivalent) and sodium bicarbonate (2 equivalents) in water (per m-difluorobenzene solution in a separate container. Add the compound in one hour at about +25 〇 CT (5) The MTBE layer is added to the solution at the same time, and the mixture is simultaneously mixed. The two-phase solution is allowed to mix and take 'one hour' and the layers are separated. The compound (6) is used as it is in the next step. Aqueous solution. Add sodium hydroxide (50% '1.2 equivalents), and bromoacetic acid (1.2 bases) to the 100288.doc -17· 1344954 water containing compound (6) In the solution, the reaction mixture (pH~8.2 〇) was heated to still +90 C, aged for 10 hours, and allowed to cool to room temperature to crystallize the product, which was filtered and passed through water (per mole of difluoro Phenylhydrazine. 5 liters) was washed and dried under vacuum at <30 to 40 ° C (melting point ~60 ° C) to give compound (7). ^ N-methylpyrrolidone (NMP, per mole compound ( 7) 8 〇〇 ml)'. Compound (7) (one equivalent), and hydrazine (35% aqueous solution, 2.5 equivalents) were placed in a round Teflon flask. The solution was heated to a high of 9 Torr &lt;t, and φ was aged under nitrogen for 6 hours. The reaction mixture was then cooled to room temperature and acetone (2 eq.) was slowly added (~1 hr). After the addition of acetone, the ruthenium begins to crystallize. After aging at room temperature for one hour, water (hours per liter of compound (7) 1.5 liters) was added. The mixture was aged for one hour, filtered, and washed twice with water, then dried at EtOAc (EtOAc) to afford compound (11). THF (1 liters per mole of compound (11) ), compound (11) (prepared), tetrabutylammonium iodide (0.03 equivalent), 4-gas benzyl gas (1.05 • equivalent), and 5N NaOH (5 equivalents) were charged into the reaction vessel. The biphasic mixture was heated to 50 ° C and stirred for 5 hours. The mixture was then cooled to room temperature and the aqueous layer was separated. The organic layer was washed with a 15% aqueous NaCI solution (1 liter per mole of compound (11)). The organic mixture was heated to still 50 C, and methanesulfonic acid (MSA, 1 丨 equivalent) was added over 0.5 hours. After the addition was completed, 0.1 weight of salt seed crystals were added to initiate the crystallization reaction. The batch mixture was aged for 2 hours and then MTBE (4 liters per mole of compound (1)) was added in one hour. After a further 2 hours at (10), the batch was allowed to cool to room temperature and aged for 2 hours. The mixture was passed through 100288.doc -18·1344954 and the filter cake was washed twice with MTBE and then dried under vacuum to give the hydrazine/MSA salt (compound (12)).

步驟3.合物(13)之製法 方法A 於至/Jtt下以一份添加化合物(3)之MTBE溶液(在MTBE中 0.813 M,1_1當量)至化合物(12)( 一當量)之乙腈(每莫耳化 • 合物(12)3.4升)漿體内。使所形成漿體脫氣,並加熱至至 φ 间+50至55 C,費時24小時。於+50。(:下添加水(每莫耳化 合物(12)340毫升)’並使該反應混合物冷卻至室溫。過減 該批混合物,先後經90/10之乙腈/水(每莫耳化合物(12)85〇 毫升)及甲醇(每莫耳化合物(12)1.7升)清洗。於+4〇至5〇它Step 3. Process for the preparation of the compound (13) A to a solution of the compound (3) in MTBE (0.813 M in MTBE, 1 to 1 equivalent) to the compound (12) (one equivalent) of acetonitrile Each mole of compound (12) 3.4 liters in the slurry. The formed slurry was degassed and heated to between +50 and 55 C between φ, which took 24 hours. At +50. (: Add water (340 ml per mole of compound (12))' and cool the reaction mixture to room temperature. Subtract the mixture and pass 90/10 acetonitrile/water (per mole compound (12) 85 ml) and methanol (1.7 liters per mole of compound (12)). Clean it at +4〇 to 5〇

下,在烘箱内乾燥該濾餅,費時24小時,得到該產物。 方法B 於20至25 °C下,按順序將化合物(12)(—當量)及化合物 (3)二異丙基胺(DIPA)鹽(當量)與丙酸(每莫耳化合物 修 (12)3.3 3升)裝入圓底燒瓶内。使該漿體溫熱至,並老 化3小時。以3至5分鐘添加甲基磺酸(1.2當量)。於5〇至6〇 °C下使該漿體老化一小時,冷卻至30它,並以約$分鐘添 加水(每莫耳化合物(12)0.33升)。使該漿體老化3〇分鐘, 並過濾。以10〇/〇水性甲醇(1 〇%水,90%甲醇,每莫耳化入 物(12)2升)洗務該淺黃色濾餅’直到該濾液呈無色為止。 以乙醇(母莫耳化合物(12) 1升)洗蘇該滤餅。使該濾餅在a 氣流中乾燥’然後於40°C下在真空烘箱内乾燥,得到該產 物。 I00288.doc -19- 1344954 化合物(13)TMG鹽之製法: 於 23 °C 下,將 1,1,3,3·四甲基胍(TMG,99%,24.5 毫 升,193毫莫耳)加入化合物(13)(70克,161毫莫耳)之異丙 基乙醯胺(IPAc ’ 280毫升)及MeOH(140毫升)漿體内,然後 使該等固體溶解。添加額外IPAc( 125毫升)以作為晶種,其 可導致漿體之形成。添加額外IPAc( 12 5毫升),並使該混合 物老化一夜。藉由同時添加IPAc使該漿體以恆定體積經蒸 φ 餾。當該上澄清液達5毫克/毫升時,中斷蒸餾,並使該漿 體在冰浴内經冷卻。過濾該結晶,經冰冷IPAc洗滌β乾燥 產生85.6克結晶狀固體’其純度為96.8重量%。 化合物(13)DBU鹽之製法: 於60°C下將DBU(99%,0.21毫升,1.36毫莫耳)加入化合 物(13)(0.50克,1.2毫莫耳)之MeOH(3毫升)漿體内,使現 在為均勻之該溶液冷卻至23 °C ’並作為晶種以導致漿體之 形成。添加MTBE(6毫升),並使該漿體老化一夜。過濾該 • 等固體,經4 : 1之MTBE/MeOH洗滌。乾燥該等固體,得 到〇_57克化合物(13)DBU鹽。 化合物(13)DBN鹽之製法: 於60°C下將DBN(98°/〇,0.33毫升,2.65毫莫耳)加入化合 物(13)(1.〇〇克,2.30毫莫耳)之MeOH(5毫升)漿體内。然後 使現在為均勻之該溶液冷卻至23。(:。緩慢添加MTBE(4毫 升)以定期誘發結晶作用。使所形成漿體老化6〇分鐘。添 加額外MTBE(11毫升)至該漿體内,並使其進一步老化。 過濾該等固體,經5 : 1之MTBE/MeOH洗滌。乾燥該等固 100288.doc -20- 1344954 體,產生0.98克化合物(13)DBN鹽。 化合物(13)鉀鹽之製法: 於23°C下將KOtBu(95%,285毫克,2.41毫莫耳)加入化 合物(13)(1.00克,2.30毫莫耳)之MeOH(5毫升)漿體内。緩 • 慢添加MTBE(5毫升)至該溶液内,並藉由0.45微米注射濾 器過濾所形成混濁溶液。添加額外MTBE至該濾液以導致 漿體之形成。使該漿體老化60分鐘。過濾該等固體,先後 φ 經5 : 1 MTBE/MeOH、及100% MTBE洗滌。乾燥該等固 體’產生0.58克化合物(13)鉀鹽。 參考實例2 當場形成觸媒之方法 釕在惰性大氣之手套箱内,將脫氣甲醇(75毫升)裝入 含[(對-繳花烴)RuC12]2(0.369克,0.60毫莫耳)及⑻·BINAp (0.770克,1.24毫莫耳)之圓底燒瓶内。添加脫氣甲苯(25毫 升)’並將該橘色不均勻溶液移至具有可再密封庚替斯 • (Kontes)接合器之安瓶内。將該安瓶密封,自該手套箱移 出,並於50至60°C下加熱1至2小時,同時攪拌。將該清析 之橘色溶液放入手套箱内,並於室溫下貯存以作為儲備溶 液([(對-繳花烴)(S-BINAP)RuC12]之莫耳濃度約為〇 〇 12)。 姥在惰性大氣之手套箱β ’將前述脫氣甲醇裝入含The filter cake was dried in an oven and took 24 hours to obtain the product. Method B Compound (12) (-equivalent) and compound (3) diisopropylamine (DIPA) salt (equivalent) and propionic acid (repair per mole compound (12) at 20 to 25 ° C 3.3 3 liters) was placed in a round bottom flask. The slurry was allowed to warm to and aging for 3 hours. Methanesulfonic acid (1.2 equivalents) was added over 3 to 5 minutes. The slurry was aged for one hour at 5 to 6 ° C, cooled to 30, and water was added for about $ minutes (0.33 liter per mole of compound (12)). The slurry was aged for 3 minutes and filtered. The light yellow filter cake was washed with 10 Torr/hydrous methanol (1% water, 90% methanol, 2 liters per liter (12)) until the filtrate was colorless. The filter cake was washed with ethanol (mole molar compound (12) 1 liter). The cake was dried in a stream of air' and then dried in a vacuum oven at 40 ° C to give the product. I00288.doc -19- 1344954 Preparation of Compound (13) TMG Salt: Add 1,1,3,3·tetramethylguanidine (TMG, 99%, 24.5 ml, 193 mmol) at 23 °C Compound (13) (70 g, 161 mmol) of isopropylacetamide (IPAc '280 mL) and MeOH (140 mL) was then taken and then dissolved. Additional IPAc (125 mL) was added as a seed which resulted in the formation of a slurry. Additional IPAc (125 mL) was added and the mixture was aged overnight. The slurry was subjected to distillation in a constant volume by simultaneous addition of IPAc. When the supernatant liquid reached 5 mg/ml, the distillation was interrupted and the slurry was cooled in an ice bath. The crystals were filtered, and dried by ice-cold IPAc washing to give 85.6 g of a crystalline solid, which had a purity of 96.8 wt. Preparation of Compound (13) DBU Salt: DBU (99%, 0.21 mL, 1.36 mmol) was added to compound (13) (0.50 g, 1.2 mmol) MeOH (3 mL). Inside, the solution, which is now homogeneous, is cooled to 23 ° C 'and serves as a seed to cause the formation of a slurry. MTBE (6 mL) was added and the slurry was aged overnight. The solid was filtered and washed with 4:1 MTBE/MeOH. The solids were dried to give 〇57 g of compound (13) DBU salt. Preparation of Compound (13) DBN Salt: DBN (98 ° / 〇, 0.33 mL, 2.65 mmol) was added to Compound (13) (1. gram, 2.30 mmol) of MeOH at 60 ° C ( 5 ml) in the body. The solution, which is now homogeneous, is then cooled to 23. (: Slowly add MTBE (4 ml) to induce crystallization on a regular basis. The resulting slurry was aged for 6 minutes. Additional MTBE (11 ml) was added to the slurry and further aged. Filter the solids, Washing with 5:1 MTBE/MeOH. Drying the solid 100288.doc -20- 1344954 to give 0.98 g of compound (13) DBN salt. Compound (13) Potassium salt: KOtBu (at 23 ° C) 95%, 285 mg, 2.41 mmol.) Compound (13) (1.00 g, 2.30 mmol) in MeOH (5 mL) was added. Slowly slowly added MTBE (5 mL) to the solution and The turbid solution was formed by filtration through a 0.45 micron syringe filter. Additional MTBE was added to the filtrate to cause the formation of a slurry. The slurry was aged for 60 minutes. The solids were filtered, followed by φ 5: 1 MTBE/MeOH, and 100 % MTBE washing. Drying the solids yielded 0.58 g of compound (13) potassium salt. Reference Example 2 Method for forming a catalyst in the field 脱In a glove box of inert atmosphere, degassed methanol (75 ml) was charged with [( Pair-paid hydrocarbons) RuC12]2 (0.369 grams, 0.60 millimoles) and (8)·BINAp (0.770 , 1.24 mmol) in a round bottom flask. Add degassed toluene (25 mL) and transfer the orange uneven solution to a ampule with a resealable Kontes adapter. The ampule is sealed, removed from the glove box, and heated at 50 to 60 ° C for 1 to 2 hours while stirring. The orange solution is placed in a glove box and stored at room temperature as a The molar concentration of the stock solution ([(----)-------------

Rh(COD)2BF2及所欲對掌配位體(! · i莫耳當量L/Rh)之圓底 燒瓶内。於室溫下攪拌該溶液,費時一小時。[觸 媒]= 0.016 Μ。 提供以下非限定實例以進一步說明本發明。 100288.doc 21 1344954 實例1 [(3R)-4-(4 -亂本基)甲基_7_氟-5-(曱基續酿基)_ι,2,3,4 -四氫 環五[b]吲哚-3-基]醋酸、TMG及DIPA鹽Rh(COD)2BF2 and the desired round ligand in the flask (! · i molar equivalent L/Rh). The solution was stirred at room temperature for one hour. [Battery] = 0.016 Μ. The following non-limiting examples are provided to further illustrate the invention. 100288.doc 21 1344954 Example 1 [(3R)-4-(4-heteroyl)methyl-7-fluoro-5-(indenyl)-,,,,,,,,,,,,,,,,, b] ind-3-yl]acetic acid, TMG and DIPA salts

TMG鹽 方法A.將化合物(13)(3.0克,6.9毫莫耳)、]^(〇11)(23 毫升)、及攪拌棒裝入反應容器内。攪拌該黃褐色漿體, 並藉由注射器添加TMG( 0.8毫升,6.9毫莫耳)。使所形成 紫色/褐色漿體脫氣(真空/氮氣X5),並將該容器放入手套 相内。藉由注射器裝填該釕觸媒[(對_繳花烴)(s_ BINAP)RuC12]2(8.1毫升,在甲醇 / 甲苯(3:1)中 〇 〇12M,j 4 莫耳/。)。將該谷器密封,自手套箱移出,並連接至氫/氮/ 真空歧管。將弓1導至壓力容器之管線脫氣(真空/氮氣X5) 後,使該壓力容器内之攪拌溶液經脫氣(氮氣/真空χ3),並 經氫氣(氫氣40 psig/真空χ3)壓力滌洗,且不需攪拌。然後 將該反應溶液置於氫氣(10 Psig)下,設定攪拌,並溫熱至 45-50°C。老化一夜(〜15小時)後,使所形成均勻溶液冷卻 至室溫,並將該壓力容器排放至常壓。ee=9i%。 方法B.在手套箱内,將化合物(13)TMC}鹽(2 5克,4 6 毫莫耳)、脫氣Me〇H(25毫升)、[(對_繳花烴)(s_ 100288.doc -22- 1344954 BINAP)RUC12]2(1.9 毫升,0·023 毫莫耳,〇 5 莫耳 %)、及撲 拌棒裝入反應壓力容器内,密封該容器,自手套箱移出, ^ 並連接至氫/氮/真空歧管。將引導至壓力容器之管線脫氣 (真空/氮氣Χ5)後,使該壓力容器經脫氣(氮氣/真空x5)c&gt;將 該容器加熱至53°C,經氫氣(氫氣/真空x3)壓力滌洗,然後 將其置於氫氣(10 Psig)下。使該攪拌漿體老化一夜(〜15小 時),然後冷卻至室溫,並將該壓力容器排放至常壓。 • ee=91% 。 DIPA 鹽 藉由氮喷洗使含化合物(13)(1.0當量)及EtOH(每莫耳化 合物(13)1升)之漿體脫氣。藉由真空將該漿體連同脫氣 Et3N(1.0當量)及脫氣Et〇H(每莫耳化合物(13)0.5升)洗滌一 夜一起裝入壓熱器内。藉由雙容器裝置(5〇〇毫升及15〇毫 升),先後將預脫氣之45% KOH(—當量)及作為洗滌液之脫 氣EtOH(100毫升)裝入該壓熱器内。然後藉由相同管線(其 # 係用於裝填觸媒)裝填得自個別施能克(Schlenk)燒瓶之預 脫氣EtOH(100毫升)。該EtOH進料必需可完全清除該進料 管線之任何會危害該觸媒之KOH。可藉由氮-真空務洗法 使該混合物脫氣,並藉由雙容器裝置(2升及15〇毫升),先 後將0.012M之S-BINAPRuC12-對-繳花烴複合物之3 : i EtOH-曱苯(0.5莫耳%)及EtOH(100毫升)洗滌液裝入壓熱器 内。於28-27°C下先後藉由氮氣壓力滌洗3次 '及氫氣壓力 滌洗3次以使該混合物脫氣。然後於5〇°c在2〇 psig下氫化 s亥混合物’直到認為反應完成為止(HPLC : &lt; 〇 1A%化合 100288.doc •23· 物(13)殘留)。 將孩粗氫化原料流(164毫克/ 旦 梦入m泛咕, 1田里對掌游離態酸) 裝入SJ底燒瓶内。使該容 磬 接媒^ ^ 欣丄6醇(母莫耳游離態酸2.9升) 。、+加DIPA(2當量)。使該溶液溫熱至55〇c。於55 C下以約-小時添加丙酸(2當量)。於饥下老化該聚體,TMG salt Method A. Compound (13) (3.0 g, 6.9 mmol), ?(〇11) (23 ml), and a stir bar were placed in a reaction vessel. The tan slurry was stirred and TMG (0.8 mL, 6.9 mmol) was added via syringe. The resulting purple/brown slurry was degassed (vacuum/nitrogen x5) and the container was placed in the glove phase. The catalyst ([__BINAP) RuC12]2 (8.1 ml, in methanol/toluene (3:1) 〇 M 12M, j 4 mol/.) was charged by syringe. The trough is sealed, removed from the glove box, and connected to a hydrogen/nitrogen/vacuum manifold. After degassing the lead 1 to the pressure vessel line (vacuum/nitrogen X5), the stirred solution in the pressure vessel is degassed (nitrogen/vacuum χ3) and pressurized with hydrogen (hydrogen 40 psig/vacuum χ3). Wash and do not need to be stirred. The reaction solution was then placed under hydrogen (10 Psig), stirred, and warmed to 45-50 °C. After aging overnight (~15 hours), the formed homogeneous solution was allowed to cool to room temperature, and the pressure vessel was discharged to normal pressure. Ee=9i%. Method B. In the glove box, compound (13) TMC} salt (25 g, 4 6 mmol), degassed Me〇H (25 ml), [(p-supplied hydrocarbon) (s_ 100288. Doc -22- 1344954 BINAP)RUC12]2 (1.9 ml, 0·023 mm, 〇5 mol%), and a blending rod into a reaction pressure vessel, sealed the container, removed from the glove box, ^ and Connect to a hydrogen/nitrogen/vacuum manifold. After degassing the line leading to the pressure vessel (vacuum/nitrogen gas 5), the pressure vessel was degassed (nitrogen/vacuum x5) c&gt; the vessel was heated to 53 ° C, and subjected to hydrogen (hydrogen/vacuum x 3) pressure. Wash and then place it under hydrogen (10 Psig). The stirred slurry was aged overnight (~15 hours), then cooled to room temperature, and the pressure vessel was discharged to atmospheric pressure. • ee=91%. DIPA salt A slurry containing compound (13) (1.0 equivalent) and EtOH (1 liter per mole of compound (13)) was degassed by nitrogen sparging. The slurry was placed in an autoclave together with degassed Et3N (1.0 eq.) and degassed Et 〇H (0.5 liter per mole of compound (13)) by vacuum overnight. The pre-degassed 45% KOH (-equivalent) and degassed EtOH (100 ml) as a washing liquid were charged into the autoclave by a two-tank apparatus (5 liters and 15 liters). Pre-degassed EtOH (100 mL) from a separate Schlenk flask was then loaded by the same line (which was used to charge the catalyst). The EtOH feed must completely remove any KOH from the feed line that would harm the catalyst. The mixture can be degassed by a nitrogen-vacuum scrubbing process and passed through a two-container unit (2 liters and 15 liters of milliliters), followed by a 0.012 M S-BINAPRuC12-p--hydrocarbon complex 3 : i EtOH-nonylbenzene (0.5 mol%) and EtOH (100 ml) washing solution were placed in an autoclave. The mixture was degassed by washing three times with nitrogen pressure at 28-27 ° C and washing with hydrogen pressure three times. The mixture was then hydrogenated at 2 ° psig at 2 ° psig until the reaction was deemed complete (HPLC: &lt; 〇 1A% compound 100288.doc •23·(13) residue). The crude hydrogenation feed stream (164 mg/dm.) was placed in a SJ bottom flask. Let the 磬 接 ^ ^ ^ 丄 6 6 alcohol (mother free ether 2.9 liters). , + plus DIPA (2 equivalents). The solution was allowed to warm to 55 〇c. Propionic acid (2 equivalents) was added at about 5 C at about 5 hours. Aging the polymer under hunger,

費時-小時’以一小時冷卻至⑽,並老化—小時。過遽 &quot;亥漿體並以冷(5 c)乙醇(每莫耳游離態酸174升)及醋酸 ^醋(每莫耳游離態酸L45升)洗務該濾餅。使該遽餅在N2 氣流内乾燥一小時,並於35_45。〇下真空乾燥。 實例2 使用姥觸媒之氫化程序:The time-hours were cooled to (10) in one hour and aged-hours. The filter cake was washed with a &lt;&quot;lurry and washed with cold (5 c) ethanol (174 liters per mole of free acid) and acetic acid vinegar (L45 liters per mole of free acid). The cake was dried in a stream of N2 for one hour and at 35-45. Dry under vacuum. Example 2 Hydrogenation procedure using a ruthenium catalyst:

在惰性大氣手套箱内,將铑觸媒溶液(在甲醇中〇.〇 16M) 轉移至含化合物(13)及鹼(例如,TMG)之曱醇溶液之壓力 容器内。密封該容器,自手套箱移出,並連接至氫/氮/真 空歧管。將導向該壓力容器之管線脫氣(真空/氮氣X5)後, 使該壓力容器脫氣(氮氣/真空X5)。使該容器經氫氣(氫氣/ 真空X3)壓力滌洗,並置於氫氣(90 psig)下。使該攪拌漿體 老化一夜(〜15小時),並將該壓力容器排放炱常壓,然後 分析。 實例3Transfer the rhodium catalyst solution (in methanol to 〇. 16M) to a pressure vessel containing the decyl alcohol solution of compound (13) and base (eg, TMG) in an inert atmosphere glove box. The container is sealed, removed from the glove box, and connected to a hydrogen/nitrogen/vacuum manifold. After the line leading to the pressure vessel was degassed (vacuum/nitrogen x5), the pressure vessel was degassed (nitrogen/vacuum X5). The vessel was subjected to a hydrogen (hydrogen/vacuum X3) pressure wash and placed under hydrogen (90 psig). The stirred slurry was aged overnight (~15 hours), and the pressure vessel was discharged at atmospheric pressure and then analyzed. Example 3

使用參考實例2之程序製備觸媒;使用實例1 ’方法A之 100288.doc • 24· 1344954The catalyst was prepared using the procedure of Reference Example 2; use Example 1 'Method A 100288.doc • 24· 1344954

程序進行氫化。 L(繳花烴)RuC12 %濃度 %ee BINAP 100 90 Solphos 92 -8 8 二曱苯基Solphos 100 -89 Synphos 96 89 TMBTP 100 -70 (R)-HexaPHEMP 100 -88 (S)-C6-TunaPhos 100 85 反應條件:1.2莫耳。/〇觸 媒,50°C ,15小時, 毫克化合物(13)/1毫升Me〇H〇已知本0/ μ炎么 匕知s % ee為負值時,所使 psig,100 用該觸媒之相對鏡像異構物可得到所欲產物 實例4 實例1化合物TMG鹽轉化成游離態酸之方法The procedure is hydrogenated. L (paid hydrocarbon) RuC12% concentration %ee BINAP 100 90 Solphos 92 -8 8 Diphenyl phenyl Solphos 100 -89 Synphos 96 89 TMBTP 100 -70 (R)-HexaPHEMP 100 -88 (S)-C6-TunaPhos 100 85 Reaction conditions: 1.2 mol. / 〇 catalyst, 50 ° C, 15 hours, milligrams of compound (13) / 1 ml Me 〇 H 〇 Know this 0 / μ 炎 匕 know s % ee is negative, so that psig, 100 use the touch The relative image isomer of the medium can give the desired product. Example 4 The method for converting the TMG salt of the compound of Example 1 into a free acid

使該含10克實例1產物分析物(95 3/4 7比率之鏡像異構 物,因此彳于到9.53克光學上純產物分析物)之該粗氫化溶液 (105.5克)經濃縮並轉化成醋酸乙酯(Ac〇Et)數次,以確保 不再殘留剩餘的MeOH/曱苯/水。將該體積調整為每克 TMG鹽為12毫升AcOEt(120毫升)。添加水(相對於^〇扮為 1 _25 V®/。: 1 _5毫升)》將該漿體加熱至至高+55,費時約 1 0小時。使該漿體冷卻至室溫’並老化丨〇小時,然後過 濾。以再循環母液沖洗該濾餅,最後經AcOEt(3 5毫升)洗 滌。在烘箱内於+40°C下乾燥,得到9.0克具有ee為〜98.5% 之TMG鹽(8.9克光學上純TMG鹽分析物;約93%產率)。使 100288.doc -25· 1344954 該乾濾餅(9克;7·1克呈自由酸)在AcOEt(90毫升)内漿體 化,並以0.5N水性HC1(90毫升)洗務以變成兩均勻層。分 離各該層’並以水(2x75毫升)洗務該有機相。以Ec〇sorb C-941(相對於自由酸為10重量%填充量,710毫克)處理所 形成AcOEt溶液。於室溫下使漿體老化一小時,並藉由 solka floe助濾劑(具AcOEt洗滌液)過濾。濃縮所形成無色 溶液’並將AcOEt之體積調整為28·4毫升,然後添加水 (142微升以得到KF〜5000)。將該批混合物加熱至至高+55 至60 °C,以使其溶解。緩慢添加正-庚烷(約8毫升)以晶 化。於+5 5 °C下使該批混合物老化約一小時,並於+55下 以1至2小時添加剩餘之正-庚烷(105 6毫升),使其老化數 小時’並使其冷卻至室溫,過濾,並經80/20之正-庚烷 /AcOEt(〜50毫升)洗滌,然後於+4〇艺下在烘箱内乾燥24小 時,得到約6.6克呈游離態酸及“為〜99·7%之產物。 實例1化合物DIPA鹽轉化成游離態酸之方法 以0.5N水性HC1(90亳升)洗滌實例1化合物DIPA鹽乾濾餅(9 克)之AcOEt(90毫升)漿體,得到兩均勻層。分離各該層,並 以水(2x75毫升)洗滌該有機相。以Ecos〇rb c-941(相對於游 離態酸為10重量%填充量,71〇毫克)處理所形成入…玢溶 液於至'狐下使忒漿體老化一小時,並藉由s〇lka floe助濾 劑(+Ac〇Et洗滌液)過濾。濃縮所形成無色溶液,並將Ac〇Ht 之體積6周製成28.4毫升,並添加水(142微升以得到〜5〇〇〇之 KF)。將忒批混合物加熱至至高+55至6〇(&gt;c以使其溶解。缓 慢添加正-庚烧(約8毫升)以得化。於+55。〇下使該批混合物 100288.doc • 26 - 1344954 老化約一小時,並於+55下以1至2小時 n ^ 听添加剩餘之正-庚烷 .耄升),老化數小時,並使其冷卻至室溫。過濾該漿 體,並經Λ ' /20之正-庚院/AcOEt(〜50毫升)洗滌。於+40 t: &quot;7^ 9 丈Η . 目内乾燥固體,費時24小時,得到6.9克所欲產 物。 100288.doc -27-The crude hydrogenation solution (105.5 grams) containing 10 grams of the product of Example 1 product (95 3/47 ratio of the mirror image isomer, thus to 9.53 grams of optically pure product analyte) was concentrated and converted to Ethyl acetate (Ac〇Et) was applied several times to ensure that no residual MeOH/indene/water remained. The volume was adjusted to 12 ml AcOEt (120 ml) per gram of TMG salt. Add water (relative to 1 _25 V®/.: 1 _5 ml). Heat the slurry to a maximum of +55, which takes about 10 hours. The slurry was allowed to cool to room temperature' and aged for an hour and then filtered. The filter cake was rinsed with recycled mother liquor and finally washed with AcOEt (35 mL). Drying at +40 ° C in an oven gave 9.0 g of TMG salt with ee of -98.5% (8.9 g of optically pure TGM salt analyte; about 93% yield). 100288.doc -25· 1344954 The dry cake (9 g; 7.1 g of free acid) was slurried in AcOEt (90 ml) and washed with 0.5 N aqueous HCl (90 mL) to become two Uniform layer. The layers were separated and washed with water (2 x 75 mL). The AcOEt solution formed was treated with Ec〇sorb C-941 (10% by weight loading relative to free acid, 710 mg). The slurry was aged for one hour at room temperature and filtered through a solka floe filter aid (with AcOEt wash). The colorless solution formed was concentrated and the volume of AcOEt was adjusted to 28.4 ml, and then water (142 μl to obtain KF to 5000) was added. The batch was heated to a temperature of +55 to 60 ° C to dissolve it. n-Heptane (about 8 ml) was slowly added to crystallize. The batch was aged at about 5 ° C for about one hour and the remaining n-heptane (105 6 ml) was added at +55 for 1 to 2 hours, allowed to age for a few hours' and allowed to cool to It was filtered at room temperature, washed with 80/20 n-heptane/AcOEt (~50 ml), and then dried in an oven for 24 hours at +4 liters to give about 6.6 g of free acid and "~99" - 7% of the product. Example 1 Method for Conversion of Compound DIPA Salt to Free Acid The slurry of Example 1 compound DIPA salt dry cake (9 g) in AcOEt (90 ml) was washed with 0.5 N aqueous HCl (90 liters). Two uniform layers. Separate each layer and wash the organic phase with water (2 x 75 mL). Treated with Ecos 〇rb c-941 (10% by weight loading relative to free acid, 71 〇 mg). The solution was aged for one hour under the 'fox, and filtered by s〇lka floe filter aid (+Ac〇Et washing solution), concentrated to form a colorless solution, and the volume of Ac〇Ht was made into 28.4. ML, and add water (142 μl to get ~5 〇〇〇KF). Heat the 忒 batch mixture to a height of +55 to 6 〇 (&gt;c Let it dissolve. Slowly add n-heptane (about 8 ml) to obtain. At +55. The batch is aged 100288.doc • 26 - 1344954 for about one hour, and at +55 for 1 to 2 Hour n ^ Listen to add the remaining n-heptane. Soar), aging for a few hours, and allow it to cool to room temperature. Filter the slurry and pass the / ' / 20 of the positive - Gengyuan / AcOEt (~ 50 ml Washing. On +40 t: &quot;7^ 9 Η Η. Drying the solid in the head, taking 24 hours, get 6.9 grams of desired product. 100288.doc -27-

Claims (1)

1344954 f 第094109815號專利申請案 中文申請專利範圍替換本(10 十、申請專利範圍: 1. 一種製備至少50%鏡像異構物過量(ee)之式I化合物或其 鹽之不對稱氫化方法 .1344954 f Patent Application No. 094,109,815 Chinese Patent Application Serial No. (10, Patent Application Range: 1. A method for the asymmetric hydrogenation of a compound of the formula I or a salt thereof in an excess of at least 50% of the image isomer excess (ee). 其中η為1或2,R1為Br或-S02CH3,且R2為Η、苄基、4_ 硝基苄基、4-胺基苄基、4-三氟曱基苄基或4-氯苄基, 該方法包括:以金屬對掌配位體及氫予體處理式II化合 物或其鹽Wherein η is 1 or 2, R1 is Br or -S02CH3, and R2 is hydrazine, benzyl, 4-nitrobenzyl, 4-aminobenzyl, 4-trifluorodecylbenzyl or 4-chlorobenzyl, The method comprises: treating a compound of formula II or a salt thereof with a metal-to-palm ligand and a hydrogen donor 其中當該氫予體為Η2時,該方法係於自約0至約500 psig(每平方英寸磅表壓)之壓力下進行,且其中該金屬 對掌配位體為(1)釕轴向對掌膦配位體複合物或(2)铑對 掌二茂鐵基膦配位體複合物或(3)鍺-TMBTP複合物。 2.如請求項1之方法,其中該金屬對掌配位體為釕軸向對 掌膦配位體複合物,且該對掌配位體係選自BINAP(式 (a),Ar=苯基)、tol-BINAP(式(a),Ar=對-曱苯基)、xyl- 100288-1000211.doc 1344954 BINAP(式(a),Ar=3,5-二曱苯基)、Synphos(式(c),Ar= 苯基)、Solphos(式(e),Ar=苯基)、MeO-BIPHEP(式 (f),Ar=苯基,Z=甲基,Ra=Rb = Rc=H)、hexaPHEMP(式 (f),Ar=苯基、Z=Ra=Rb=甲基,RC=H)、C(l-6)-tunaphos(式(g),Ar=苯基,且 n為 1 至 6)、P-Phos(式(i), Ar=苯基)、xyl-P-Phos(式(i),Ar=3,5-二曱苯基)及 TMBTP(式(h),Ar=笨基),Wherein when the hydrogen donor is ruthenium 2, the process is carried out at a pressure of from about 0 to about 500 psig (pounds per square inch), and wherein the metal to palm ligand is (1) 钌 axial a palladium phosphine ligand complex or (2) a ruthenium ferrocene phosphine ligand complex or a (3) 锗-TMBTP complex. 2. The method of claim 1, wherein the metal-to-palm ligand is a ruthenium-antimony-phosphine ligand complex, and the palm-coordination system is selected from BINAP (formula (a), Ar=phenyl ), tol-BINAP (formula (a), Ar=p-phenylene), xyl-100288-1000211.doc 1344954 BINAP (formula (a), Ar=3,5-diphenyl), Synphos (c), Ar = phenyl), Solphos (formula (e), Ar = phenyl), MeO-BIPHEP (formula (f), Ar = phenyl, Z = methyl, Ra = Rb = Rc = H) , hexaPHEMP (formula (f), Ar = phenyl, Z = Ra = Rb = methyl, RC = H), C (l-6) - tunaphos (formula (g), Ar = phenyl, and n is 1 To 6), P-Phos (formula (i), Ar = phenyl), xyl-P-Phos (formula (i), Ar = 3,5-diphenyl) and TMBTP (formula (h), Ar = stupid base), -2 100288-1000211.doc 1344954 3.如請求項1之方法,其中該金屬對掌配位體為(對-繳花 烴)Ru(S)-BINAP-C12,其中BINAP 為式(a),且 Ar=苯基,3. The method of claim 1, wherein the metal-to-palm ligand is (p--hydrocarbon) Ru(S)-BINAP-C12, wherein BINAP is formula (a), And Ar = phenyl, 4. 如請求項1之方法,其中該金屬對掌配位體為(對掌配位 體)RuX2,其中X於各次出現時,係獨立選自α、Br、 I、三氟曱磺酸根、醋酸根、甲磺酸根、笨磺酸根、 BF4、及B(Ar)4,且Ar為苯基、間-或對-甲苯基、二曱苯 基及甲氧基苯基。 5. 如請求項1之方法,其中該金屬對掌配位基為铑-二茂鐵 基膦配位體複合物,且該二茂鐵基膦配位體係選自式 (m)之 f-BINAPHANE、式(j)之 Walphos,其中…及!^各為 曱基或三氟甲基、式(k)之josiphos、及式(1)之 taniaphos,4. The method of claim 1, wherein the metal-to-palm ligand is (for palm ligand) RuX2, wherein X is independently selected from the group consisting of α, Br, I, trifluorosulfonate , acetate, mesylate, sulfonate, BF4, and B(Ar)4, and Ar is phenyl, m- or p-tolyl, diphenylene and methoxyphenyl. 5. The method of claim 1, wherein the metal-to-palm ligand is a ruthenium-ferrocenyl phosphine ligand complex, and the ferrocenyl phosphine coordination system is selected from the group consisting of f- of formula (m) BINAPHANE, Walphos of formula (j), wherein ... and !^ each are fluorenyl or trifluoromethyl, josiphos of formula (k), and taniaphos of formula (1), 100288-1000211.doc 6. 如請求項 複合物100288-1000211.doc 6. As requested, compound 1之方法,其中該金屬對掌配位體為铑-TMBTP ’其中TMBTP為式(h),且Ar=苯基, 如明求項1之方法,其中該氫化反應係於鹼存在下及視 鸹要於I族或π族鹽存在下進行。 ^備至少50%鏡像異構物過量(ee)之式la化合物或其 鹽之不對稱氫化方法The method of claim 1, wherein the metal-to-palm ligand is 铑-TMBTP ' wherein TMBTP is formula (h), and Ar = phenyl, as in the method of claim 1, wherein the hydrogenation reaction is in the presence of a base and It is carried out in the presence of a Group I or π group salt. A method for asymmetric hydrogenation of a compound of formula la or a salt thereof having at least 50% of an image isomer excess (ee) 其包· 、 ·以金屬對掌配立體及氫予體處理式Ila化合物或 其鹽Its package, · metal-to-palm stereo and hydrogen donor treatment of Ila compounds or their salts 中田該氣予體為H2時’本方法係於自約〇至約500 psig(每 平方英寸%表壓)之壓力下進行,且其中該金屬對掌配位 體為(1)釕軸向對掌膦配位體複合物或(2)铑對掌性二茂 鐵基麟配位體複合物或(3)鍺-TMBTP複合物。 月求項8之方法’其中該氫化反應係於驗存在下,使 100288-1000211.doc 13449.54 用氫進行,且其中該金屬對掌配位體係選自(1)具有 BINAP(式(a),Ar=苯基)、tol-BINAP(式(a),Ar=對-曱苯 基)、xyl-BINAP(式(a),Ar=3,5-二曱苯基)、Synphos(式 (c),Ar=苯基)、Solphos(式(e),Ar=苯基)、MeO-BIPHEP(式(f),Ar=苯基,Z=甲基,Ra=Rb=Rc=H)、 hexaPHEMP(式(f),Ar=苯基 ' Z=Ra=Rb=曱基,Re=H)、When Zhongtian's gas is H2, the method is carried out at a pressure from about to about 500 psig (per square inch of gauge pressure), and wherein the metal-to-palm ligand is (1) 钌 axial pair a palm phosphine ligand complex or (2) a ruthenium ferrocene-based rib ligand complex or a (3) 锗-TMBTP complex. The method of claim 8 wherein the hydrogenation reaction is carried out in the presence of 100288-1000211.doc 13449.54 with hydrogen, and wherein the metal-to-palm coordination system is selected from the group consisting of (1) having BINAP (formula (a), Ar = phenyl), tol-BINAP (formula (a), Ar = p-nonylphenyl), xyl-BINAP (formula (a), Ar = 3,5-diphenyl), Synphos (formula (c) ), Ar = phenyl), Solphos (formula (e), Ar = phenyl), MeO-BIPHEP (formula (f), Ar = phenyl, Z = methyl, Ra = Rb = Rc = H), hexaPHEMP (Formula (f), Ar = phenyl 'Z = Ra = Rb = sulfhydryl, Re = H), C(l-6)-tunaphos(式(g),Ar=苯基,且 n 為 1 至 6)、P-Phos(式(i) ’ Ar=苯基)、xyl-P-Phos(式(i),Ar=3,5-二甲 苯基)或TMBTP(式(h),Ar=苯基)之釕複合物,C(l-6)-tunaphos (formula (g), Ar=phenyl, and n is 1 to 6), P-Phos (formula (i) 'Ar=phenyl), xyl-P-Phos (formula i) a ruthenium complex of Ar = 3,5-dimethylphenyl) or TMBTP (formula (h), Ar = phenyl), RbRb 100288-1000211.doc 1344954100288-1000211.doc 1344954 (2)具有 f-BINAPHANE(式(m))、Walphos(式(j),其中 Rd&amp; Re各為曱基或三氟曱基)、式(k)之josiphos、式(1)之 taniaphos之錢複合物(2) having f-BINAPHANE (formula (m)), Walphos (formula (j), wherein each of Rd&amp; Re is a mercapto or trifluoromethyl), josiphos of formula (k), taniaphos of formula (1) Money complex PAr2PAr2 PAr2 或 TMBTP(式(h),Ar=苯基), 。 10. 如請求項8之方法,其中該氫化反應係於自約〇至約20 psig之壓力下進行。 11. 一種式II化合物或其鹽: 100288-1000211.doc -6- 1344954PAr2 or TMBTP (formula (h), Ar = phenyl), . 10. The method of claim 8, wherein the hydrogenating reaction is carried out at a pressure of from about Torr to about 20 psig. 11. A compound of formula II or a salt thereof: 100288-1000211.doc -6- 1344954 其中η、R1及R2如請求項1之定義。 中η為1,R1為 12.如請求項1 1之化合物或其鹽,其 -S02CH3,且R2為4-氯苄基。Where η, R1 and R2 are as defined in claim 1. Wherein η is 1 and R1 is 12. The compound of claim 1 or a salt thereof, -S02CH3, and R2 is 4-chlorobenzyl. 100288-1000211.doc100288-1000211.doc
TW094109815A 2004-04-02 2005-03-29 Asymmetric hydrogenation process TWI344954B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55897204P 2004-04-02 2004-04-02

Publications (2)

Publication Number Publication Date
TW200606145A TW200606145A (en) 2006-02-16
TWI344954B true TWI344954B (en) 2011-07-11

Family

ID=34964828

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094109815A TWI344954B (en) 2004-04-02 2005-03-29 Asymmetric hydrogenation process

Country Status (19)

Country Link
US (1) US7576118B2 (en)
EP (1) EP1737820B1 (en)
JP (1) JP5239071B2 (en)
CN (1) CN1942440B (en)
AR (1) AR048459A1 (en)
AT (1) ATE384046T1 (en)
AU (1) AU2005230897B2 (en)
BR (1) BRPI0509384A (en)
CA (1) CA2561632A1 (en)
CY (1) CY1107223T1 (en)
DE (1) DE602005004393T2 (en)
DK (1) DK1737820T3 (en)
ES (1) ES2297695T3 (en)
HR (1) HRP20080145T3 (en)
PL (1) PL1737820T3 (en)
PT (1) PT1737820E (en)
SI (1) SI1737820T1 (en)
TW (1) TWI344954B (en)
WO (1) WO2005097745A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104311472B9 (en) 2008-07-23 2020-03-17 艾尼纳制药公司 Substituted 1,2,3, 4-tetrahydrocyclopenta [ b ] indol-3-yl acetic acid derivatives
SI2342205T1 (en) 2008-08-27 2016-09-30 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
WO2011094008A1 (en) * 2010-01-27 2011-08-04 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CN105503882B (en) 2010-03-03 2019-07-05 艾尼纳制药公司 The method for preparing S1P1 receptor modulators and its crystal form
CN102659664B (en) * 2012-03-28 2015-01-21 中国计量学院 Method for synthesizing and separating Laalo Perrin and analogues thereof
NZ734220A (en) 2015-01-06 2022-01-28 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
IL285890B (en) 2015-06-22 2022-07-01 Arena Pharm Inc Crystalline free-plate habit of l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid
CA3053416A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
JP2020507611A (en) 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ, インコーポレイテッド Compounds and methods for the treatment of primary biliary cholangitis
US11555015B2 (en) 2018-09-06 2023-01-17 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0272787B1 (en) 1986-11-14 1992-05-06 Takasago International Corporation Catalytic production of optically active carboxylic acid
AR038136A1 (en) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc CYCLALCANINDOLS WITH REPLACEMENT WITH FLUOR COMPOSITIONS CONTAINING THESE COMPOUNDS AND TREATMENT METHODS
DE602004026597D1 (en) * 2003-08-07 2010-05-27 Merck Sharp & Dohme TREATMENT OF ALZHEIMER DISEASE AND RELATED STATES

Also Published As

Publication number Publication date
ES2297695T3 (en) 2008-05-01
AR048459A1 (en) 2006-04-26
WO2005097745A1 (en) 2005-10-20
US7576118B2 (en) 2009-08-18
ATE384046T1 (en) 2008-02-15
JP2007532488A (en) 2007-11-15
DK1737820T3 (en) 2008-04-28
CN1942440B (en) 2011-09-14
PL1737820T3 (en) 2008-05-30
EP1737820B1 (en) 2008-01-16
US20050222428A1 (en) 2005-10-06
AU2005230897B2 (en) 2011-03-03
JP5239071B2 (en) 2013-07-17
HRP20080145T3 (en) 2008-04-30
SI1737820T1 (en) 2008-04-30
EP1737820A1 (en) 2007-01-03
BRPI0509384A (en) 2007-09-18
DE602005004393D1 (en) 2008-03-06
CA2561632A1 (en) 2005-10-20
AU2005230897A1 (en) 2005-10-20
PT1737820E (en) 2008-03-17
TW200606145A (en) 2006-02-16
DE602005004393T2 (en) 2009-01-08
CN1942440A (en) 2007-04-04
CY1107223T1 (en) 2012-11-21

Similar Documents

Publication Publication Date Title
TWI344954B (en) Asymmetric hydrogenation process
US8969558B2 (en) Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
JP5964756B2 (en) Selective androgen receptor modulator
EP0876350A1 (en) Pyrazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives
Tan et al. Catalytic asymmetric synthesis of tetrahydrocarbazoles
JP2004522718A (en) Hydrogen transfer process and catalyst
Mitchell et al. Development and a practical synthesis of the JAK2 inhibitor LY2784544
Wan et al. Regio-and enantioselective ring-opening reaction of vinylcyclopropanes with indoles under cooperative catalysis
EP0748326B1 (en) Optically active diphosphines and method for preparing same by resolution of the racemic mixture
EP1828110A1 (en) Process for the preparation of tamsulosin and intermediates thereof
TW201630881A (en) A process for the manufacture of idalopirdine
Hobson et al. The Synthesis of a 5HT2C Receptor Agonist
JP4422808B2 (en) Trans- (R, R) -actinol
CN102548955B (en) Process for preparing cinacalcet
US6979742B1 (en) Process for obtaining enantiomers of thienylazolylalcoxyethanamines
NL1013183C2 (en) Catalyst for asymmetric transfer hydrogenation.
EP2763991B1 (en) Method for preparing 2-amino-5-ethynylpyridine
JP4531353B2 (en) Method for producing mono-N-sulfonylated diamine, solution of the compound, and hydrogenation catalyst
EP0968220A1 (en) 6,6&#39;-bis-(1-phosphanorbornadiene) diphosphines
WO2003104186A1 (en) PROCESS FOR PRODUCING OPTICALLY ACTIVE ß-AMINO ALCOHOL
Sau et al. Ruthenium-Catalyzed Chiral Sulfoximine Directed One-pot Asymmetric Multiple CH Functionalizations
Liang et al. Discovery and Development of a Highly Potent, Orally Bioavailable Estrogen Receptor Full Antagonist and Degrader: Giredestrant (GDC-9545) for Estrogen Receptor-Positive Breast Cancer
CN117305866A (en) Synthesis method of N-benzyl diaryl sulfoxide imine compound
JP2023544439A (en) Asymmetric transfer hydrogenation of 2-aryl substituted bicyclic pyridine ketones in the presence of chiral ruthenium catalysts
CA3164262A1 (en) Ligands for transition metal catalysts

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees